Literature DB >> 21997998

The sustained influence of short term exposure to a proprietary extract of North American ginseng on the hemopoietic cells of the bone marrow, spleen and blood of adult and juvenile mice.

Sandra C Miller1, Lianping Ti, Jacqueline J Shan.   

Abstract

This study assessed the influences of CVT-E002, a proprietary extract of North American ginseng, Panax quinquefolius (Afexa Life Sciences, Inc., Edmonton, AB, Canada), in vivo, on murine hemopoietic and immune cells when administered as a dietary additive. The extract was given daily to young, adult mice for a period of 4 weeks, immediately following which one group was euthanized and the hemopoietic and immune cells of their bone marrow, spleen and blood were assayed for CVT-E002-mediated alterations in any of five cell lineages (lymphocytes, nucleated erythroid cells, granulocytes, immature granuloid precursors and monocytes). Another group of these mice was left for a subsequent 8 weeks on control diet, following which the same organs and cell lineages were analysed. In another study, juvenile mice immediately upon weaning (age: 4 weeks), were subjected to the above protocol, and their organs/cell lineages assayed. The results revealed that CVT-E002 had a long-lasting, positive quantitative effect on the lymphocytes and monocytes, regardless of age at commencement of daily, dietary CVT-E002. CVT-E002 may therefore have a prophylactic disease defense, immunostimulatory role, or potentially, even a therapeutic role.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21997998     DOI: 10.1002/ptr.3626

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  3 in total

1.  Stimulation and suppression of innate immune function by American ginseng polysaccharides: biological relevance and identification of bioactives.

Authors:  Chike G Azike; Paul A Charpentier; Edmund M K Lui
Journal:  Pharm Res       Date:  2014-09-11       Impact factor: 4.200

2.  Has aidi injection the attenuation and synergistic efficacy to gemcitabine and cisplatin in non-small cell lung cancer? A meta-analysis of 36 randomized controlled trials.

Authors:  Zheng Xiao; Chengqiong Wang; Ling Chen; Xuemei Tang; Lianhong Li; Nana Li; Jing Li; Qihai Gong; Fushan Tang; Jihong Feng; Xiaofei Li
Journal:  Oncotarget       Date:  2017-01-03

3.  Clinical Efficacy and Safety of Aidi Injection Plus Docetaxel-Based Chemotherapy in Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis of 36 Randomized Controlled Trials.

Authors:  Zheng Xiao; Chengqiong Wang; Lianhong Li; Xuemei Tang; Nana Li; Jing Li; Ling Chen; Qihai Gong; Fushan Tang; Jihong Feng; Xiaofei Li
Journal:  Evid Based Complement Alternat Med       Date:  2018-06-11       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.